Published online Oct 15, 2014. doi: 10.4251/wjgo.v6.i10.407
Revised: April 17, 2014
Accepted: September 16, 2014
Published online: October 15, 2014
Colorectal peritoneal carcinomatosis was considered a terminal condition with a merely palliative treatment that included only supportive care, palliative surgery and the best systemic chemotherapy. Since the birth of a new approach, cytoreductive surgery with peritonectomy procedures together with hyperthermic intraperitoneal chemotherapy and/or early postoperative intraperitoneal chemotherapy to treat peritoneal carcinomatosis, many research groups contributed with promising results using this procedure being up to date this strategy the only one that has shown curative benefits on colorectal peritoneal carcinomatosis achieving reported overall survival rates up to 64 mo and five-year survival rates up to 51%. The aim of this paper is to expose an updated overview of the therapeutic possibilities of these procedures in colorectal peritoneal metastases in the same way that our Unit of Oncologic Surgery has performed since 1997 with more than four hundred procedures.
Core tip: The carcinomatosis peritoneal from colon origin has turned from a terminal condition to a curative scenery. The cytoreduction and peritonectomy procedures with hyperthermic intraperitoneal chemotherapy have achieved 50% in 5 years overall survival, with a low morbidity that is not higher than other major surgical procedures.